These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19327024)

  • 41. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
    Wu XZ; Xie GR; Chen D
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cinnamic Acid Derivatives Enhance the Efficacy of Transarterial Embolization in a Rat Model of Hepatocellular Carcinoma.
    Wilkins LR; Brautigan DL; Wu H; Yarmohammadi H; Kubicka E; Serbulea V; Leitinger N; Liu W; Haaga JR
    Cardiovasc Intervent Radiol; 2017 Mar; 40(3):430-437. PubMed ID: 27872984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of transcatheter arterial embolization therapy for small hepatocellular carcinomas: comparison with other treatments.
    Arai K; Matsui O; Takashima T; Kadoya M; Yoshikawa J; Gabata T; Ueda K; Kawamori Y; Izumi R; Kobayashi K
    Radiat Med; 1990; 8(5):191-8. PubMed ID: 1963696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastasis-Associated Protein 1 Is Involved in Angiogenesis after Transarterial Chemoembolization Treatment.
    Xue T; Feng W; Yu H; Zhu M; Fei M; Bao Y; Wang X; Ma W; Lv G; Guan J; Chen S
    Biomed Res Int; 2017; 2017():6757898. PubMed ID: 28589145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma.
    Gade TPF; Tucker E; Nakazawa MS; Hunt SJ; Wong W; Krock B; Weber CN; Nadolski GJ; Clark TWI; Soulen MC; Furth EE; Winkler JD; Amaravadi RK; Simon MC
    Radiology; 2017 Jun; 283(3):702-710. PubMed ID: 28253108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antisense hypoxia inducible factor-1alpha and B7-1 combination gene therapy for mouse lymphoma].
    Sun XY; Meng FQ; Jiang HC; Qiao HQ; Li W
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):404-7. PubMed ID: 16188124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RNA interference-mediated downregulation of hypoxia-inducible factor-1α inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo.
    Zhou H; Fei W; Bai Y; Zhu S; Luo E; Chen K; Hu J
    Eur J Cancer Prev; 2012 May; 21(3):289-99. PubMed ID: 22113109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance.
    Yasuda S; Arii S; Mori A; Isobe N; Yang W; Oe H; Fujimoto A; Yonenaga Y; Sakashita H; Imamura M
    J Hepatol; 2004 Jan; 40(1):117-23. PubMed ID: 14672622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modified Rat Hepatocellular Carcinoma Models Overexpressing Vascular Endothelial Growth Factor.
    Choi JW; Cho HR; Lee K; Jung JK; Kim HC
    J Vasc Interv Radiol; 2018 Nov; 29(11):1604-1612. PubMed ID: 30293733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma.
    Gunji T; Kawauchi N; Akahane M; Watanabe K; Kanamori H; Ohnishi S
    Int J Oncol; 2002 Aug; 21(2):427-32. PubMed ID: 12118341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Transcatheter arterial embolization with hepatic arterial induction of endogenous TNF in hepatocellular carcinoma].
    Takekoshi H; Oyama R
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2845-8. PubMed ID: 2476966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization.
    Kim YB; Park YN; Park C
    Histopathology; 2001 Feb; 38(2):160-6. PubMed ID: 11207829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma.
    Liu Q; Fan D; Adah D; Wu Z; Liu R; Yan QT; Zhang Y; Du ZY; Wang D; Li Y; Bao SY; Liu LP
    Oncol Rep; 2018 Nov; 40(5):2547-2557. PubMed ID: 30226584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats.
    Wu HP; Feng GS; Liang HM; Zheng CS; Li X
    World J Gastroenterol; 2004 Mar; 10(6):813-8. PubMed ID: 15040023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors.
    Dai F; Zhang X; Shen W; Chen J; Liu L; Gao G
    Onco Targets Ther; 2015; 8():2601-11. PubMed ID: 26451117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma.
    Dong ZZ; Yao M; Wang L; Wu W; Gu X; Yao DF
    Mini Rev Med Chem; 2013 Jul; 13(9):1295-304. PubMed ID: 22512580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma.
    Huynh KN; Rao S; Roth B; Bryan T; Fernando DM; Dayyani F; Imagawa D; Abi-Jaoudeh N
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization.
    Zhu L; Liu R; Zhang W; Qian S; Wang J
    Clin Transl Oncol; 2018 May; 20(5):639-646. PubMed ID: 29022239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcatheter arterial embolization promotes liver tumor metastasis by increasing the population of circulating tumor cells.
    Fang ZT; Wang GZ; Zhang W; Qu XD; Liu R; Qian S; Zhu L; Zhou B; Wang JH
    Onco Targets Ther; 2013; 6():1563-72. PubMed ID: 24235842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis.
    Andrade FO; Furtado KS; Heidor R; Sandri S; Hebeda CB; Miranda MLP; Fernandes LHG; Yamamoto RC; Horst MA; Farsky SHP; Moreno FS
    Carcinogenesis; 2019 Aug; 40(8):979-988. PubMed ID: 30590392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.